Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

被引：2
|
作者：
Gutierrez, M. E. [1 ]
Giaccone, G. [2 ]
Liu, S. V. [2 ]
Rajan, A. [3 ]
Guha, U. [3 ]
Halfdanarson, T. R. [4 ]
Curtis, K. K. [5 ]
Kunz, P. L. [6 ]
Gabrail, N. [7 ]
Hinson, J. M. [8 ]
Orlemans, E. O. [9 ]
机构：
[1] John Theurer Canc Ctr, Hematol & Oncol, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Canc Ctr, Hematol & Oncol, Washington, DC USA
[3] NCI, Thorac & Gastrointestinal Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[4] Mayo Clin, Med, Rochester, MN USA
[5] Mayo Clin, Internal Med, Scottsdale, AZ USA
[6] Stanford Univ, Sch Med, Med Oncol, Palo Alto, CA 94304 USA
[7] Gabrail Canc Ctr, Hematol, Canton, OH USA
[8] Unicorn Pharma Consulting, Clin Res, Nashville, TN USA
[9] Esanex Inc, Clin Res, Indianapolis, IN USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw369.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial
    Giordano, Frank A.
    Brehmer, Stefanie
    Muerle, Bettina
    Welzel, Grit
    Sperk, Elena
    Keller, Anke
    Abo-Madyan, Yasser
    Scherzinger, Elisabeth
    Clausen, Sven
    Schneider, Frank
    Herskind, Carsten
    Glas, Martin
    Seiz-Rosenhagen, Marcel
    Groden, Christoph
    Haenggi, Daniel
    Schmiedek, Peter
    Emami, Bahman
    Souhami, Luis
    Petrecca, Kevin
    Wenz, Frederik
    NEUROSURGERY, 2019, 84 (01) : 41 - 49
  • [32] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [33] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [34] A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
    Blackman, Samuel C.
    Gainer, Shelby D.
    Suttle, Benjamin B.
    Skordos, Konstantine W.
    Greshock, Joel D.
    Motwani, Monica
    Roadcap, Lori T.
    Hardwicke, Mary Ann A.
    Wooster, Richard F.
    CANCER RESEARCH, 2012, 72
  • [35] Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
    Kollmannsberger, C.
    Hirte, H.
    Siu, L. L.
    Mazurka, J.
    Chi, K.
    Elit, L.
    Walsh, W.
    Sederias, J.
    Doyle, A.
    Eisenhauer, E. A.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 238 - 244
  • [36] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
    Kudo, Toshihiro
    Murai, Yoshiyuki
    Kojima, Yoshitsugu
    Uehara, Kenji
    Satoh, Taroh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
  • [37] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    LEUKEMIA, 2017, 31 (02) : 393 - 402
  • [38] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [39] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
  • [40] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    S Verstovsek
    M Talpaz
    E Ritchie
    M Wadleigh
    O Odenike
    C Jamieson
    B Stein
    T Uno
    R A Mesa
    Leukemia, 2017, 31 : 393 - 402
12345